← Library
Vasopressin / Terlipressin
FDA ApprovedSince 2014
Also known as Vasostrict, Lucassin
Function
Primary
Vasodilatory Shock · Hepatorenal Syndrome
Mechanism
V1a receptor agonist causing vasoconstriction; V2 receptor antidiuretic action; terlipressin is a prodrug.
Evidence
Clinical RCT (Phase III)
Research
Phase III CONFIRM (terlipressin)
Dosing
Range
0.01–0.07 units/min (IV infusion)
Frequency
Continuous IV
Route
Intravenous
Cycling
ICU-only; titrated infusion, no cycling.
Benefits
- ·Restoration of vascular tone in shock
- ·Improved renal function in HRS-1
- ·Catecholamine-sparing
Risks
- ·Mesenteric/digital ischemia
- ·Hyponatremia
- ·Cardiac arrhythmia
- ·Respiratory failure in ARDS
Contraindications
- ·Severe coronary artery disease
- ·Hypovolemic shock untreated
Regulatory
FDA-Approved Rx
Cited Works
- Wong F et al. Terlipressin plus Albumin for Hepatorenal Syndrome Type 1 (CONFIRM). N Engl J Med. 2021;384:818.source